Cargando…
Outcomes of patients with bone metastases from differentiated thyroid cancer
OBJECTIVE: Bone metastases (BM) from differentiated thyroid cancer (DTC) are associated with poor survival rates. Due to the low frequency of this entity, we performed a multicentric retrospective study that aimed to evaluate the presentation, outcome and causes of death in this population. SUBJECTS...
Autores principales: | Califano, Inés, Deutsch, Susana, Löwenstein, Alicia, Cabezón, Carmen, Pitoia, Fabián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118682/ https://www.ncbi.nlm.nih.gov/pubmed/29694635 http://dx.doi.org/10.20945/2359-3997000000004 |
Ejemplares similares
-
Selective use of sorafenib in the treatment of thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2016) -
Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017) -
Current Management of Bone Metastases from Differentiated Thyroid Cancer
por: Kato, Satoshi, et al.
Publicado: (2021) -
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021) -
Thyroid cancer in the Era of COVID-19
por: Smulever, Anabella, et al.
Publicado: (2020)